Moreover, atorvastatin enhanced the anti-proliferative effect of gefitinib and osimertinib in TKI-sensitive, EGFR-mutated NSCLC models and overcame EGFR gefitinib resistance in H1975 cells [83]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.